Effects of Delgocitinib Ointment 0.5% on the Normal Mouse Skin and Epidermal Tight Junction Proteins in Comparison With Topical Corticosteroids

DOI Web Site Web Site 5 Citations
  • Akiko Anagawa-Nakamura
    Tobacco Inc, Toxicology Research Laboratories, Central Pharmaceutical Research Institute, Kanagawa, Japan
  • Katsunori Ryoke
    Tobacco Inc, Toxicology Research Laboratories, Central Pharmaceutical Research Institute, Kanagawa, Japan
  • Yuzo Yasui
    Tobacco Inc, Toxicology Research Laboratories, Central Pharmaceutical Research Institute, Kanagawa, Japan
  • Toshiyuki Shoda
    Tobacco Inc, Toxicology Research Laboratories, Central Pharmaceutical Research Institute, Kanagawa, Japan
  • Shoichiro Sugai
    Tobacco Inc, Toxicology Research Laboratories, Central Pharmaceutical Research Institute, Kanagawa, Japan

Search this article

Description

<jats:p> Delgocitinib ointment 0.5% is the world’s first topical Janus kinase inhibitor product and was approved for treatment of atopic dermatitis (AD) in Japan. Although topical corticosteroids (TCSs) have been the mainstay of pharmacotherapy in AD over the past decades, long-term use of TCSs causes skin atrophy and alteration of the epidermal tight junction (TJ) leading to epidermal barrier dysfunction. In this study, delgocitinib ointment 0.5% or representative TCSs of different potencies were applied dermally once daily to the ear pinna of normal ICR mice for 14 days, and ear pinna thickness, histopathology, and immunohistochemistry for epidermal TJ proteins claudin-1 and -4 were evaluated. All the TCSs caused decreases in ear pinna thickness with epidermal thinning, sebaceous gland atrophy, and atrophy/decreased number of the subcutaneous adipocytes and decreased immunohistochemical staining intensity for epidermal claudins. In contrast, delgocitinib ointment 0.5% did not cause any of those changes. In conclusion, once daily topical delgocitinib ointment 0.5% for 14 days did not cause skin atrophy or decreased immunohistochemical staining of epidermal claudins, which are common safety concerns associated with TCSs. These characteristics suggest that delgocitinib ointment 0.5% has an improved safety profile over currently available TCS therapies particular for the long-term AD treatment. </jats:p>

Journal

Citations (5)*help

See more

Report a problem

Back to top